| Application no. and date | 21152314.7 (espacenet) (Federated) (European Patent Register), 20111202 | | Patent/reg. no. and date | DK/EP 3884947, 20231115 | | Publication date | 20210929 | | Priority no. and date | US 41939510 P, 20101203 | | EP pub. no. and date |
EP 3884947 20210929 | | Effective date | | | Applicant/owner | Nalpropion Pharmaceuticals LLC, 155 Franklin Rd, Suite 450
Brentwood, TN 37027, US | | Applicant ref. no. | P83939DK01 | | Inventor | FLANAGAN,, Shawn, 14083 Via Corsini
San Diego,, CA California 92128, US,
DUNAYEVICH,, Eduardo, 1030 Deep Wood Drive
Westlake Village,, CA California 91362, US | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 31/137 (2006.01) , A61K 31/485 (2006.01) , A61K 45/06 (2006.01) , A61P 3/04 (2006.01) | | Title | FORØGELSE AF LÆGEMIDDELBIOTILGÆNGELIGHED I NALTREXONTERAPI | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
